aTyr Pharma, Inc.
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company has a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
- Ticker
- ATYR
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dr. Sanjay S. Shukla M.D., M.S.
- Headquarters
- 10240 Sorrento Valley Road, San Diego, CA, United States, 92121
- Employees
- 58
- Website
- https://atyrpharma.com
Metrics
Analyst Insights & forecasts
Based on information from 9 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | -$0.14 | -$0.11 | -$0.11 |
| Expected | -$0.18 | -$0.14 | -$0.15 |
| Surprise | 22.22% | 22.81% | 26.67% |
| Beat | Beat | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $-10.3M | $-18.3M | 77.14% |
| Profit margin | -∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a aTyr Pharma, Inc. share?
aTyr Pharma, Inc. shares are currently traded for undefined per share.
02How many shares does aTyr Pharma, Inc. have?
aTyr Pharma, Inc. currently has 2.5M shares.
03Does aTyr Pharma, Inc. pay dividends?
No, aTyr Pharma, Inc. doesn't pay dividends.
04What is aTyr Pharma, Inc. 52 week high?
aTyr Pharma, Inc. 52 week high is $44.40.
05What is aTyr Pharma, Inc. 52 week low?
aTyr Pharma, Inc. 52 week low is $4.07.
06What is the 200-day moving average of aTyr Pharma, Inc.?
aTyr Pharma, Inc. 200-day moving average is $23.42.
07Who is aTyr Pharma, Inc. CEO?
The CEO of aTyr Pharma, Inc. is Dr. Sanjay S. Shukla M.D., M.S..
08How many employees aTyr Pharma, Inc. has?
aTyr Pharma, Inc. has 58 employees.
09What is the market cap of aTyr Pharma, Inc.?
The market cap of aTyr Pharma, Inc. is $17.3M.
10What is the P/E of aTyr Pharma, Inc.?
The current P/E of aTyr Pharma, Inc. is null.
11What is the EPS of aTyr Pharma, Inc.?
The EPS of aTyr Pharma, Inc. is -$20.18.
12What is the PEG Ratio of aTyr Pharma, Inc.?
The PEG Ratio of aTyr Pharma, Inc. is null.
13What do analysts say about aTyr Pharma, Inc.?
According to the analysts aTyr Pharma, Inc. is considered a hold.
